Nature:MERS-CoV与CD26受体的结合

2013-08-08 Nature中文网 Nature中文网

到2013年7月中旬,被最近出现的类似SARS的“中东呼吸综合症冠状病毒” (MERS-CoV) 感染的90个病例已被确认,其中包括43个死亡病例。ACE2 (angiotensin converting enzyme 2) 对SARS冠状病毒起一个细胞表面受体的作用,但MERS-CoV的功能受体是“二肽基肽酶-4”,亦称为CD26。这篇论文介绍了MERS-CoV刺突蛋白的受体结合域的晶体结构(包

到2013年7月中旬,被最近出现的类似SARS的“中东呼吸综合症冠状病毒” (MERS-CoV) 感染的90个病例已被确认,其中包括43个死亡病例。ACE2 (angiotensin converting enzyme 2) 对SARS冠状病毒起一个细胞表面受体的作用,但MERS-CoV的功能受体是“二肽基肽酶-4”,亦称为CD26。这篇论文介绍了MERS-CoV刺突蛋白的受体结合域的晶体结构(包括自由状态和与该受体相结合状态的结构)。这些结构显示了一个“核心子域”,与SARS-CoV刺突蛋白的“核心子域”同源,同时还显示了一个独特的、由链支配的(strand-dominated)外部受体结合主题,其作用是识别CD26。一个适当折叠的“受体结合域”也许具有用在一种MERS-CoV疫苗中、充当一个“免疫原”的潜力。

原始出处:

Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, Zhang Y, Zhang W, Yuan Y, Bao J, Zhang B, Shi Y, Yan J, Gao GF.Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26.Nature. 2013 Jul 7. doi: 10.1038/nature12328.

点击下载PDF文件:PDF文件

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879618, encodeId=f03618e961833, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 28 01:13:00 CST 2013, time=2013-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878063, encodeId=1eed18e8063d7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 29 18:13:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773406, encodeId=dd4c1e7340671, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Sat Jul 12 00:13:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016635, encodeId=3ede20166355b, content=<a href='/topic/show?id=61b6429988' target=_blank style='color:#2F92EE;'>#CD26#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4299, encryptionId=61b6429988, topicName=CD26)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Fri Jun 27 05:13:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338399, encodeId=17fb1338399b6, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sat Aug 10 08:13:00 CST 2013, time=2013-08-10, status=1, ipAttribution=)]
    2013-10-28 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879618, encodeId=f03618e961833, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 28 01:13:00 CST 2013, time=2013-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878063, encodeId=1eed18e8063d7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 29 18:13:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773406, encodeId=dd4c1e7340671, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Sat Jul 12 00:13:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016635, encodeId=3ede20166355b, content=<a href='/topic/show?id=61b6429988' target=_blank style='color:#2F92EE;'>#CD26#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4299, encryptionId=61b6429988, topicName=CD26)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Fri Jun 27 05:13:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338399, encodeId=17fb1338399b6, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sat Aug 10 08:13:00 CST 2013, time=2013-08-10, status=1, ipAttribution=)]
    2014-04-29 anminleiryan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879618, encodeId=f03618e961833, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 28 01:13:00 CST 2013, time=2013-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878063, encodeId=1eed18e8063d7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 29 18:13:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773406, encodeId=dd4c1e7340671, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Sat Jul 12 00:13:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016635, encodeId=3ede20166355b, content=<a href='/topic/show?id=61b6429988' target=_blank style='color:#2F92EE;'>#CD26#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4299, encryptionId=61b6429988, topicName=CD26)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Fri Jun 27 05:13:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338399, encodeId=17fb1338399b6, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sat Aug 10 08:13:00 CST 2013, time=2013-08-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1879618, encodeId=f03618e961833, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 28 01:13:00 CST 2013, time=2013-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878063, encodeId=1eed18e8063d7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 29 18:13:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773406, encodeId=dd4c1e7340671, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Sat Jul 12 00:13:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016635, encodeId=3ede20166355b, content=<a href='/topic/show?id=61b6429988' target=_blank style='color:#2F92EE;'>#CD26#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4299, encryptionId=61b6429988, topicName=CD26)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Fri Jun 27 05:13:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338399, encodeId=17fb1338399b6, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sat Aug 10 08:13:00 CST 2013, time=2013-08-10, status=1, ipAttribution=)]
    2014-06-27 dongjia2010
  5. [GetPortalCommentsPageByObjectIdResponse(id=1879618, encodeId=f03618e961833, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Oct 28 01:13:00 CST 2013, time=2013-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878063, encodeId=1eed18e8063d7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 29 18:13:00 CST 2014, time=2014-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773406, encodeId=dd4c1e7340671, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Sat Jul 12 00:13:00 CST 2014, time=2014-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016635, encodeId=3ede20166355b, content=<a href='/topic/show?id=61b6429988' target=_blank style='color:#2F92EE;'>#CD26#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4299, encryptionId=61b6429988, topicName=CD26)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Fri Jun 27 05:13:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338399, encodeId=17fb1338399b6, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Sat Aug 10 08:13:00 CST 2013, time=2013-08-10, status=1, ipAttribution=)]

相关资讯

Science:中国学者揭示细菌细胞分裂机制

7月26日,来自中国浙江大学的科学家们通过一系列实验证实,细菌细胞一分为二的分裂过程主要由一种蛋白产生的机械能所驱动。这一研究成果于7月26日发表于美国《科学》杂志,题为《FtsZ原丝纤维通过轴转机制而产生分裂力》。 细胞由一个母细胞分裂为两个子细胞的发生机制一直广受科学家关注。此前已有研究证实,细胞分裂时,母细胞中间会先产生一个由“FtsZ蛋白”组成的环状结构,这个环状结构被称为“收缩之环”或

JBC:罗成等阐明金黄色葡萄球菌ClpP水解酶的分子机制

上海药物所抗菌交叉团队研究人员针对金黄色葡萄球蛋白水解酶ClpP(SaClpP),开展水解功能的分子机制研究,继2011年在美国生物化学和分子生物学学会专业期刊Journal of Biological Chemistry上发表论文之后,研究论文再次发表于该杂志(J Biol Chem,2013,288,17643–53)。 ClpP是细菌中关键的蛋白水解系统,由上下两个七聚体自组装成一个球形腔

J. Immunol.:诱导HIV的免疫应答研究中取得新进展

中科院武汉病毒研究所胡勤学学科组在HIV免疫应答研究中取得新进展,相关结果作为封面论文于2013年8月发表在免疫学领域期刊The Journal of Immunology上。 HIV疫苗的研究经历近三十年,但目前仍没有有效的HIV疫苗问世。HIV包膜糖蛋白(Env)是预防性疫苗的首选靶标,然而,多种形式的Env均不能诱导机体产生高水平的广谱中和能力。增强抗原免疫原性的手段之一是选用合适的佐剂。

JBC:李斌等发现人源CD4+ T细胞中决定炎症因子IFNg表达的新调节通路

近日,国际学术期刊Journal of Biological Chemistry在线发表了中科院上海巴斯德研究所李斌课题组的研究论文,题为TIP60 Positively Regulates ThPOK-Mediated Repression of Eomesodermin in Human CD4+ T Cells。本研究揭示了一个抑制炎症因子IFNg转录表达的TIP60-ThPOK-Eomes

Nat Commun:节制饮食使肠道微生物群更健康

本期Nature Communications上发表的一篇论文报告说,限制热量促进肠道细菌的生长,同时实验鼠的寿命也会有所延长。这一发现表明,限制热量也许会通过诱导一个健康的肠道微生物群来增强其对宿主的健康促进效应。 通过减少食物摄取限制热量已知能延长一系列模型生物的寿命。肠道微生物群在宿主健康和疾病中所起作用正在越来越多地被认识到,其组成主要由饮食决定。Liping Zhao让小鼠终生采用一种

Vaccine:黄忠等发现柯萨奇A16型病毒的保护性抗体表位

日前,国际学术期刊《疫苗学》Vaccine在线发表了上海巴斯德所黄忠研究组题为“Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16”的研究论文。该论文首次报道了柯萨奇A16型病毒(CA16)的保守线性中和表位,为设计针对CA16的广谱性多肽疫苗奠定